Fluorescein versus Indocyanine Green Angiography Guided Half-Dose Photodynamic Therapy for Chronic Central Serous Chorioretinopathy

被引:1
|
作者
Moodi, Farzan [1 ,2 ]
Naseripour, Masood [1 ,2 ,3 ]
Zand, Amin [1 ,2 ]
Mirshahi, Reza [1 ,2 ]
Moodi, Vihan [4 ]
Alemzadeh, Sayyed Amirpooya [1 ,2 ]
Falavarjani, Khalil Ghasemi [1 ,2 ,3 ,5 ]
机构
[1] Iran Univ Med Sci, Senses Hlth Inst 5, Eye Res Ctr, Rassoul Akram Hosp,Sch Med, Tehran, Iran
[2] Iran Univ Med Sci, Senses Hlth Inst 5, Dept Ophthalmol, Rassoul Akram Hosp,Sch Med, Tehran, Iran
[3] Iran Univ Med Sci, Stem Cell & Regenerat Med Res Ctr, Tehran, Iran
[4] Univ Tehran Med Sci, Sch Med, Tehran, Iran
[5] Rassoul Akram Hosp, Eye Res Ctr, Sattarkhan Niaiesh St, Tehran 14456, Iran
关键词
Central Serous Chorioretinopathy; Fluorescein Angiography; Indocyanine Green Angiography; Photodynamic Therapy; VERTEPORFIN;
D O I
10.18502/jovr.v19i1.15420
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To compare the outcomes of fluorescein angiography (FA)-guided and indocyanine green angiography (ICGA)-guided half-dose photodynamic therapy (PDT) in patients with chronic central serous chorioretinopathy (CSC). Methods: In this retrospective comparative study, medical records of eyes with chronic CSC who underwent half-dose PDT were reviewed. A retina specialist performed FA-guided half-dose PDT, and the other performed ICGA-guided treatment. The success of applying PDT in the resolution of subretinal fluid was compared between the FA- and ICGA-guided methods. Results: Eighty-two eyes of 73 patients (41 eyes in each group) received half-dose PDT. After halfdose PDT, a significant improvement in the best-corrected visual acuity (BCVA) was found at the time of the last follow-up in both groups (both P < 0.001), with no significant intergroup difference. Central subfield and subfoveal choroidal thicknesses decreased significantly in both groups at the last follow-up (all P < 0.05), with no significant differences between the groups. Subretinal fluid (SRF) resolved in all eyes, and no persistent SRF was detected during the follow-up period. Conclusion: FA-guided and ICG-guided half-dose PDT may have similar efficacy for the treatment of chronic CSC.
引用
收藏
页码:12 / 17
页数:6
相关论文
共 50 条
  • [21] Half-Dose Verteporfin Photodynamic Therapy (hdPDT) in the Treatment of Central Serous Chorioretinopathy
    Hoehn, F.
    Kretz, F. T. A.
    Beger, I.
    Koch, F.
    Auffarth, G. U.
    Singh, P.
    Deuchler, S.
    Koss, M. J.
    KLINISCHE MONATSBLATTER FUR AUGENHEILKUNDE, 2016, 233 (07) : 860 - 863
  • [22] COMPARISON OF PHOTODYNAMIC THERAPY USING HALF-DOSE OF VERTEPORFIN OR HALF-FLUENCE OF LASER LIGHT FOR THE TREATMENT OF CHRONIC CENTRAL SEROUS CHORIORETINOPATHY
    Cheng, Cheng-Kuo
    Chang, Chun-Kai
    Peng, Chi-Hsien
    RETINA-THE JOURNAL OF RETINAL AND VITREOUS DISEASES, 2017, 37 (02): : 325 - 333
  • [23] Subthreshold micropulse laser photocoagulation versus half-dose photodynamic therapy for acute central serous chorioretinopathy
    Zeng, Miao
    Chen, Xiao
    Song, Yanping
    Cai, Chunyan
    BMC OPHTHALMOLOGY, 2022, 22 (01)
  • [24] Half-Dose Photodynamic Therapy Targeting the Leakage Point on the Fluorescein Angiography in Acute Central Serous Chorioretinopathy: A Pilot Study
    Kim, Kyu Seop
    Lee, Won Ki
    Lee, Seung Bum
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2014, 157 (02) : 366 - 373
  • [25] Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy
    van Rijssen, Thomas J.
    van Dijk, Elon H. C.
    Scholz, Paula
    MacLaren, Robert E.
    Fauser, Sascha
    Downes, Susan M.
    Hoyng, Carel B.
    Boon, Camiel J. F.
    GRAEFES ARCHIVE FOR CLINICAL AND EXPERIMENTAL OPHTHALMOLOGY, 2021, 259 (04) : 905 - 910
  • [26] Choroidal neovascularization secondary to half-dose photodynamic therapy for chronic central serous chorioretinopathy A case report
    Zhang, Zhengwei
    Bao, Xiaona
    Wu, Zhifeng
    Zhang, Jie
    MEDICINE, 2021, 100 (07) : E24790
  • [27] Outcome of half-dose photodynamic therapy in chronic central serous chorioretinopathy with fovea-involving atrophy
    Thomas J. van Rijssen
    Elon H. C. van Dijk
    Paula Scholz
    Robert E. MacLaren
    Sascha Fauser
    Susan M. Downes
    Carel B. Hoyng
    Camiel J. F. Boon
    Graefe's Archive for Clinical and Experimental Ophthalmology, 2021, 259 : 905 - 910
  • [28] Long-term results of half-dose photodynamic therapy for chronic central serous chorioretinopathy with contrast sensitivity changes
    Karakus, S. H.
    Basarir, B.
    Pinarci, E. Y.
    Kirandi, E. U.
    Demirok, A.
    EYE, 2013, 27 (05) : 612 - 620
  • [29] Association Between the Efficacy of Half-Dose Photodynamic Therapy With Indocyanine Green Angiography and Optical Coherence Tomography Findings in the Treatment of Central Serous Chorioretinopathy
    Nicolo, Massimo
    Zoli, Daniela
    Musolino, Maria
    Traverso, Carlo Enrico
    AMERICAN JOURNAL OF OPHTHALMOLOGY, 2012, 153 (03) : 474 - 480
  • [30] Photoreceptor disruption in central serous chorioretinopathy treated by half-dose photodynamic therapy
    Ratanasukon, Mansing
    Thongthong, Koblarp
    Bhurayanontachai, Patama
    Jirarattanasopa, Pichai
    CLINICAL OPHTHALMOLOGY, 2013, 7 : 87 - 92